194 related articles for article (PubMed ID: 28367662)
1. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients.
D'Arena G; Simeon V; Laurenti L; Cimminiello M; Innocenti I; Gilio M; Padula A; Vigliotti ML; De Lorenzo S; Loseto G; Passarelli A; Di Minno MND; Tucci M; De Feo V; D'Auria F; Silvestris F; Di Minno G; Musto P
Leuk Lymphoma; 2017 Nov; 58(11):2633-2641. PubMed ID: 28367662
[TBL] [Abstract][Full Text] [Related]
2. Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders.
Tudesq JJ; Cartron G; Rivière S; Morquin D; Iordache L; Mahr A; Pourcher V; Klouche K; Cerutti D; Le Quellec A; Guilpain P
Autoimmun Rev; 2018 Feb; 17(2):115-124. PubMed ID: 29180125
[TBL] [Abstract][Full Text] [Related]
3. Use of Patient and Disease Characteristics as Predictive Indicators of Rituximab Infusion-Related Reactions in Adult Malignant Hematology Patients at an Academic Medical Center.
Kowalski KE; Adams CB; Voils SA; Wheeler SE
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):723-728. PubMed ID: 31530473
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and predictors of infusion-related reactions to rituximab in patients with B-cell non-Hodgkin lymphoma.
Faqeer N; Alrabie R; Al-Haddadin R; Ma'koseh M
J Chemother; 2024 Jul; 36(4):291-298. PubMed ID: 37860948
[TBL] [Abstract][Full Text] [Related]
6. Rituximab desensitization in three patients with severe rituximab allergy.
Öztürk E; Özyiğit LP; Öztürk AB; Akay MO; Çetiner M; Ferhanoğlu B
Curr Probl Cancer; 2017; 41(5):349-354. PubMed ID: 28860080
[TBL] [Abstract][Full Text] [Related]
7. Enteroviral infection in patients treated with rituximab for non-Hodgkin lymphoma: a case series and review of the literature.
Grisariu S; Vaxman I; Gatt M; Elias S; Avni B; Arad A; Pasvolsky O; Raanani P; Paltiel O
Hematol Oncol; 2017 Dec; 35(4):591-598. PubMed ID: 27734521
[TBL] [Abstract][Full Text] [Related]
8. Rapid rituximab infusion is safe in paediatric and young adult patients with non-malignant indications.
Wallace G; Myers KC; Davies SM; Teusink A; Jodele S
Br J Haematol; 2016 May; 173(3):480-1. PubMed ID: 26205134
[No Abstract] [Full Text] [Related]
9. A tale of two antibodies: obinutuzumab versus rituximab.
Freeman CL; Sehn LH
Br J Haematol; 2018 Jul; 182(1):29-45. PubMed ID: 29741753
[TBL] [Abstract][Full Text] [Related]
10. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
[TBL] [Abstract][Full Text] [Related]
11. Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.
Chaoui D; Choquet S; Sanhes L; Mahé B; Hacini M; Fitoussi O; Arkam Y; Orfeuvre H; Dilhuydy MS; Barry M; Jourdan E; Dreyfus B; Tempescul A; Leprêtre S; Bardet A; Leconte P; Maynadié M; Delmer A
Leuk Lymphoma; 2017 Jun; 58(6):1366-1375. PubMed ID: 28271952
[TBL] [Abstract][Full Text] [Related]
12. [Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia].
Šimkovič M; Vodárek P; Motyčková M; Žák P; Smolej L
Vnitr Lek; 2015; 61(7-8):626-32. PubMed ID: 26375688
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.
Davies A; Berge C; Boehnke A; Dadabhoy A; Lugtenburg P; Rule S; Rummel M; McIntyre C; Smith R; Badoux X
Adv Ther; 2017 Oct; 34(10):2210-2231. PubMed ID: 28983819
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study on the management of patients with rituximab refractory follicular lymphoma.
Solal-Céligny P; Leconte P; Bardet A; Hernandez J; Troussard X
Br J Haematol; 2018 Jan; 180(2):217-223. PubMed ID: 29230799
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU).
Witzig TE; Johnston PB; LaPlant BR; Kurtin PJ; Pederson LD; Moore DF; Nabbout NH; Nikcevich DA; Rowland KM; Grothey A
Am J Hematol; 2017 Oct; 92(10):1004-1010. PubMed ID: 28614905
[TBL] [Abstract][Full Text] [Related]
16. Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12.
Baetz T; Chen BE; Couban S; Tom Kouroukis C; Buckstein R; Kuruvilla J; Howson-Jan K; Szwajcer D; Federico M; Meyer RM; Djurfeldt MS; Hay AE; Shepherd L; Crump M
Leuk Lymphoma; 2017 Jan; 58(1):64-69. PubMed ID: 27266754
[TBL] [Abstract][Full Text] [Related]
17. Real word evidence on rituximab utilization: Combining administrative and hospital-pharmacy data.
Roberto G; Spini A; Bartolini C; Moscatelli V; Barchielli A; Paoletti D; Giorgi S; Fabbri A; Bocchia M; Donnini S; Gini R; Ziche M
PLoS One; 2020; 15(3):e0229973. PubMed ID: 32163477
[TBL] [Abstract][Full Text] [Related]
18. Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry.
Mocikova H; Pytlik R; Sykorova A; Janikova A; Prochazka V; Vokurka S; Berkova A; Belada D; Campr V; Buresova L; Trneny M;
Leuk Lymphoma; 2016 Dec; 57(12):2777-2783. PubMed ID: 27087066
[TBL] [Abstract][Full Text] [Related]
19. Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.
Gleeson M; Hawkes EA; Peckitt C; Wotherspoon A; Attygalle A; Sharma B; Du Y; Ethell M; Potter M; Dearden C; Horwich A; Chau I; Cunningham D
Leuk Lymphoma; 2017 Aug; 58(8):1805-1813. PubMed ID: 27931133
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma.
Nagai H; Shimomura T; Takeuchi M; Hanada S; Komeno T; Sunami K; Hidaka M; Yano T; Kitano K; Yoshida I; Inoue N; Saito A; Horibe K; Motitani S; Ichihara S; Watanabe T; Sawamura M
Leuk Lymphoma; 2017 Dec; 58(12):2845-2851. PubMed ID: 28509595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
